NCT03106324 2025-11-24
A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant
Celgene
Active not recruiting
Clinical Trials
16 trialsNCT07206810 2025-10-03
A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
The First Affiliated Hospital of Soochow University
Completed
NCT06163040 2025-07-31
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Bristol-Myers Squibb
Completed
NCT03098589 2025-03-30
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
Celgene
Completed
NCT04036448 2025-03-11
RevlimidPMS
Celgene
Completed
NCT03647124 2025-03-04
A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Celgene
Completed
NCT05923879 2023-06-28
Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
Ruijin Hospital
Unknown
NCT05899621 2023-06-12
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
Ruijin Hospital
Recruiting
NCT05883709 2023-06-01
A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL
Ruijin Hospital
Unknown
NCT05690191 2023-01-19
Chidamide in Patients With Recurrent and Refractory Diffuse Large b
Second Affiliated Hospital of Soochow University
Enrolling by invitation
NCT05495620 2022-08-10
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
Dong-A University Hospital
Unknown
NCT04109872 2020-02-05
Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Unknown
NCT01752075 2019-11-18
A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan
Celgene
Completed
NCT03715296 2019-07-08
Lenalidomide Based Immunotherapy in the Treatment of DLBCL
Ruijin Hospital
Unknown
NCT02556905 2017-12-04
A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea
Celgene
Completed
NCT01947309 2017-01-12
Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
Celgene
Terminated